Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer

Recruiting N/A Interventional Study
Early-stage Breast Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Female
Study type
Interventional
Purpose
Treatment
Participants needed
300 (estimated)
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This study is a prospective, multi-center, open-label cohort study, with 3 years disease free survival(DFS) as the primary endpoint. We optimize post-operation adjuvant therapy for early stage breast cancer based on the MRD strategy: patients with clinical high risk or post-operation 1st MRD tested positive will receive intensive adjuvant therapy, while patients with low clinical risk and post-ope…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Subjects aged ≥18 years (inclusive). * Histologically confirmed, perioperative invasive breast cancer that is resectable without metastasis(stage I-III). * No anti-breast cancer systematic therapy received, and planning to receive surgery and systemic therapy. * Eastern Cooper…
Contacts

Fei Ma

86-10-87788060

drmafei@126.com

CONTACT

Hongnan Mo

86-10-87788120

CONTACT